Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX69 in refractory ovarian cancer with malignant ascites
NCT02540356Phase 2Terminated
- Sponsor
- Takeda
- Start
- Nov 2015
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of imalumab in ovarian cancer and malignant ascites (2 arms), sponsored by Takeda. Primary endpoints: Occurrence of Dose-limiting Toxicity at 4 weeks and Ratio of Puncture Free Survival (PuFS) Over Puncture-free Interval at Baseline at 4 weeks. Started Nov 2015; status: terminated.
02
Drugs
imalumab
03
Conditions
ovarian cancermalignant ascites
Beyond the preview
Go deeper on NCT02540356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02540356.